CA
NZ
UK
AU
IND
US
DexCom, Inc. (NASDAQ: DXCM) appointed Glenn S. Boehnlein to its board effective September 10, 2026, alongside an initial equity grant with a fair value of $500,000. The appointment gives Boehnlein a board term ending at the 2027 annual meeting and adds him to two …
Disc Medicine, Inc. (NASDAQ: IRON) reported that mean hematocrit in Cohort A remained below 45% through 26 weeks in initial RESTORE-PV Phase 2 results for DISC-3405. The company said the result was accompanied by an initial improvement in symptom burden. DISC-3405 also reduced phlebotomy …
DR REDDYS LABORATORIES LTD (NYSE: RDY) allotted 375 fully paid equity shares on September 10, 2026, following eligible employee exercises under its stock option programme. The shares rank equally with existing equity.
Elevance Health, Inc. (NYSE: ELV) is reaffirming full-year 2026 shareholders’ earnings guidance of at least $20.10 per diluted share.
EXELIXIS, INC. (NASDAQ: EXEL) said the FDA extended its review of zanzalintinib with atezolizumab for metastatic colorectal cancer by three months.
GeoVax Labs, Inc. (NASDAQ: GOVX) will appeal its Nasdaq delisting determination at a Hearings Panel session scheduled for October 13, 2026.
Gossamer Bio, Inc. (NASDAQ: GOSS) completed a 1-for-80 reverse stock split, converting every 80 outstanding common shares into one share. The move is intended to help the stock meet Nasdaq’s $1.00 minimum closing bid requirement before the October 5 compliance date.
IceCure Medical Ltd. (NASDAQ: ICCM) can market its ProSense system in China after receiving approval from the National Medical Products Administration on September 10, 2026. The authorization covers the system and its associated cryoprobes under the approved registration.
AtaiBeckley Inc. (NASDAQ: ATAI) completed its merger with Eli Lilly and Company (NYSE: LLY) on September 11, 2026, becoming aWholly Owned Subsidiaryof Lilly. Each eligible common share converted into $6.75 in cash plus one contingent value right that can pay up to $2.50 per …
Axogen, Inc. (NASDAQ: AXGN) agreed to acquire BioCircuit Technologies for a base cash purchase price of $200.0 million. The transaction would make BioCircuit a wholly owned subsidiary, while Axogen intends to use substantially all net proceeds from a common-stock offering to fund the cash …
Please wait processing your request...